Global Drugs for Non-Small Cell Lung Cancer Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Drugs for Non-Small Cell Lung Cancer Industry Forecast” looks at past sales and reviews total world Drugs for Non-Small Cell Lung Cancer sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Non-Small Cell Lung Cancer sales for 2023 through 2029. With Drugs for Non-Small Cell Lung Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Non-Small Cell Lung Cancer industry.

This Insight Report provides a comprehensive analysis of the global Drugs for Non-Small Cell Lung Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Non-Small Cell Lung Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Non-Small Cell Lung Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Non-Small Cell Lung Cancer and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Non-Small Cell Lung Cancer.

The global Drugs for Non-Small Cell Lung Cancer market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Drugs for Non-Small Cell Lung Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Drugs for Non-Small Cell Lung Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Drugs for Non-Small Cell Lung Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Drugs for Non-Small Cell Lung Cancer players cover Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex and BioMarin Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Non-Small Cell Lung Cancer market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
    Radiofrequency Ablation (RFA)
    Radiation Therapy
    Chemotherapy
    Targeted Therapies
    Immunotherapy

Segmentation by application
    Hospitals
    Clinics
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Bristol-Myers Squibb
    GlaxoSmithKline
    Menarini
    Sanofi
    Ziopharm Oncology
    Alchemia
    Amgen
    Apotex
    BioMarin Pharmaceutical
    CellAct Pharma
    Cerulean Pharma
    Cipla
    Cornerstone Pharmaceuticals
    Curis
    CytRx
    Eli Lilly
    Exelixis
    Fresenius Kabi
    Genentech
    Hikma Pharmaceuticals
    Hospira
    Intas Pharmaceuticals
    Karyopharm Therapeutics
    Kyowa Hakko Kirin
    Ligand Pharmaceuticals

List of Tables
    Table 1. Drugs for Non-Small Cell Lung Cancer Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
    Table 2. Major Players of Radiofrequency Ablation (RFA)
    Table 3. Major Players of Radiation Therapy
    Table 4. Major Players of Chemotherapy
    Table 5. Major Players of Targeted Therapies
    Table 6. Major Players of Immunotherapy
    Table 7. Drugs for Non-Small Cell Lung Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
    Table 8. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & ($ Millions)
    Table 9. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Table 10. Drugs for Non-Small Cell Lung Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
    Table 11. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & ($ Millions)
    Table 12. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Table 13. Global Drugs for Non-Small Cell Lung Cancer Revenue by Players (2018-2023) & ($ Millions)
    Table 14. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Player (2018-2023)
    Table 15. Drugs for Non-Small Cell Lung Cancer Key Players Head office and Products Offered
    Table 16. Drugs for Non-Small Cell Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    Table 17. New Products and Potential Entrants
    Table 18. Mergers & Acquisitions, Expansion
    Table 19. Global Drugs for Non-Small Cell Lung Cancer Market Size by Regions 2018-2023 & ($ Millions)
    Table 20. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Regions (2018-2023)
    Table 21. Global Drugs for Non-Small Cell Lung Cancer Revenue by Country/Region (2018-2023) & ($ millions)
    Table 22. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Country/Region (2018-2023)
    Table 23. Americas Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & ($ Millions)
    Table 24. Americas Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Country (2018-2023)
    Table 25. Americas Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & ($ Millions)
    Table 26. Americas Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Table 27. Americas Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & ($ Millions)
    Table 28. Americas Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Table 29. APAC Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2023) & ($ Millions)
    Table 30. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Region (2018-2023)
    Table 31. APAC Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & ($ Millions)
    Table 32. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Table 33. APAC Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & ($ Millions)
    Table 34. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Table 35. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2018-2023) & ($ Millions)
    Table 36. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Country (2018-2023)
    Table 37. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & ($ Millions)
    Table 38. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Table 39. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & ($ Millions)
    Table 40. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Table 41. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Region (2018-2023) & ($ Millions)
    Table 42. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Region (2018-2023)
    Table 43. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2018-2023) & ($ Millions)
    Table 44. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Table 45. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2018-2023) & ($ Millions)
    Table 46. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Table 47. Key Market Drivers & Growth Opportunities of Drugs for Non-Small Cell Lung Cancer
    Table 48. Key Market Challenges & Risks of Drugs for Non-Small Cell Lung Cancer
    Table 49. Key Industry Trends of Drugs for Non-Small Cell Lung Cancer
    Table 50. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Regions (2024-2029) & ($ Millions)
    Table 51. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share Forecast by Regions (2024-2029)
    Table 52. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2024-2029) & ($ Millions)
    Table 53. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Application (2024-2029) & ($ Millions)
    Table 54. Bristol-Myers Squibb Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 55. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 56. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 57. Bristol-Myers Squibb Main Business
    Table 58. Bristol-Myers Squibb Latest Developments
    Table 59. GlaxoSmithKline Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 60. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 61. GlaxoSmithKline Main Business
    Table 62. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 63. GlaxoSmithKline Latest Developments
    Table 64. Menarini Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 65. Menarini Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 66. Menarini Main Business
    Table 67. Menarini Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 68. Menarini Latest Developments
    Table 69. Sanofi Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 70. Sanofi Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 71. Sanofi Main Business
    Table 72. Sanofi Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 73. Sanofi Latest Developments
    Table 74. Ziopharm Oncology Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 75. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 76. Ziopharm Oncology Main Business
    Table 77. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 78. Ziopharm Oncology Latest Developments
    Table 79. Alchemia Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 80. Alchemia Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 81. Alchemia Main Business
    Table 82. Alchemia Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 83. Alchemia Latest Developments
    Table 84. Amgen Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 85. Amgen Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 86. Amgen Main Business
    Table 87. Amgen Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 88. Amgen Latest Developments
    Table 89. Apotex Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 90. Apotex Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 91. Apotex Main Business
    Table 92. Apotex Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 93. Apotex Latest Developments
    Table 94. BioMarin Pharmaceutical Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 95. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 96. BioMarin Pharmaceutical Main Business
    Table 97. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 98. BioMarin Pharmaceutical Latest Developments
    Table 99. CellAct Pharma Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 100. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 101. CellAct Pharma Main Business
    Table 102. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 103. CellAct Pharma Latest Developments
    Table 104. Cerulean Pharma Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 105. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 106. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 107. Cerulean Pharma Main Business
    Table 108. Cerulean Pharma Latest Developments
    Table 109. Cipla Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 110. Cipla Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 111. Cipla Main Business
    Table 112. Cipla Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 113. Cipla Latest Developments
    Table 114. Cornerstone Pharmaceuticals Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 115. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 116. Cornerstone Pharmaceuticals Main Business
    Table 117. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 118. Cornerstone Pharmaceuticals Latest Developments
    Table 119. Curis Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 120. Curis Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 121. Curis Main Business
    Table 122. Curis Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 123. Curis Latest Developments
    Table 124. CytRx Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 125. CytRx Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 126. CytRx Main Business
    Table 127. CytRx Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 128. CytRx Latest Developments
    Table 129. Eli Lilly Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 130. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 131. Eli Lilly Main Business
    Table 132. Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 133. Eli Lilly Latest Developments
    Table 134. Exelixis Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 135. Exelixis Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 136. Exelixis Main Business
    Table 137. Exelixis Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 138. Exelixis Latest Developments
    Table 139. Fresenius Kabi Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 140. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 141. Fresenius Kabi Main Business
    Table 142. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 143. Fresenius Kabi Latest Developments
    Table 144. Genentech Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 145. Genentech Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 146. Genentech Main Business
    Table 147. Genentech Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 148. Genentech Latest Developments
    Table 149. Hikma Pharmaceuticals Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 150. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 151. Hikma Pharmaceuticals Main Business
    Table 152. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 153. Hikma Pharmaceuticals Latest Developments
    Table 154. Hospira Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 155. Hospira Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 156. Hospira Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 157. Hospira Main Business
    Table 158. Hospira Latest Developments
    Table 159. Intas Pharmaceuticals Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 160. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 161. Intas Pharmaceuticals Main Business
    Table 162. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 163. Intas Pharmaceuticals Latest Developments
    Table 164. Karyopharm Therapeutics Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 165. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 166. Karyopharm Therapeutics Main Business
    Table 167. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 168. Karyopharm Therapeutics Latest Developments
    Table 169. Kyowa Hakko Kirin Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 170. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 171. Kyowa Hakko Kirin Main Business
    Table 172. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 173. Kyowa Hakko Kirin Latest Developments
    Table 174. Ligand Pharmaceuticals Details, Company Type, Drugs for Non-Small Cell Lung Cancer Area Served and Its Competitors
    Table 175. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Offered
    Table 176. Ligand Pharmaceuticals Main Business
    Table 177. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
    Table 178. Ligand Pharmaceuticals Latest Developments
List of Figures
    Figure 1. Drugs for Non-Small Cell Lung Cancer Report Years Considered
    Figure 2. Research Objectives
    Figure 3. Research Methodology
    Figure 4. Research Process and Data Source
    Figure 5. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2018-2029 ($ Millions)
    Figure 6. Drugs for Non-Small Cell Lung Cancer Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
    Figure 7. Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country/Region (2022)
    Figure 8. Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country/Region (2018, 2022 & 2029)
    Figure 9. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type in 2022
    Figure 10. Drugs for Non-Small Cell Lung Cancer in Hospitals
    Figure 11. Global Drugs for Non-Small Cell Lung Cancer Market: Hospitals (2018-2023) & ($ Millions)
    Figure 12. Drugs for Non-Small Cell Lung Cancer in Clinics
    Figure 13. Global Drugs for Non-Small Cell Lung Cancer Market: Clinics (2018-2023) & ($ Millions)
    Figure 14. Drugs for Non-Small Cell Lung Cancer in Other
    Figure 15. Global Drugs for Non-Small Cell Lung Cancer Market: Other (2018-2023) & ($ Millions)
    Figure 16. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application in 2022
    Figure 17. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Player in 2022
    Figure 18. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Regions (2018-2023)
    Figure 19. Americas Drugs for Non-Small Cell Lung Cancer Market Size 2018-2023 ($ Millions)
    Figure 20. APAC Drugs for Non-Small Cell Lung Cancer Market Size 2018-2023 ($ Millions)
    Figure 21. Europe Drugs for Non-Small Cell Lung Cancer Market Size 2018-2023 ($ Millions)
    Figure 22. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size 2018-2023 ($ Millions)
    Figure 23. Americas Drugs for Non-Small Cell Lung Cancer Value Market Share by Country in 2022
    Figure 24. United States Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 25. Canada Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 26. Mexico Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 27. Brazil Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 28. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Region in 2022
    Figure 29. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type in 2022
    Figure 30. APAC Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application in 2022
    Figure 31. China Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 32. Japan Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 33. Korea Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 34. Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 35. India Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 36. Australia Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 37. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Country in 2022
    Figure 38. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Figure 39. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Figure 40. Germany Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 41. France Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 42. UK Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 43. Italy Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 44. Russia Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 45. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Region (2018-2023)
    Figure 46. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2018-2023)
    Figure 47. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2018-2023)
    Figure 48. Egypt Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 49. South Africa Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 50. Israel Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 51. Turkey Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 52. GCC Country Drugs for Non-Small Cell Lung Cancer Market Size Growth 2018-2023 ($ Millions)
    Figure 53. Americas Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 54. APAC Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 55. Europe Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 56. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 57. United States Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 58. Canada Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 59. Mexico Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 60. Brazil Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 61. China Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 62. Japan Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 63. Korea Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 64. Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 65. India Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 66. Australia Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 67. Germany Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 68. France Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 69. UK Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 70. Italy Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 71. Russia Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 72. Spain Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 73. Egypt Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 74. South Africa Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 75. Israel Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 76. Turkey Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 77. GCC Countries Drugs for Non-Small Cell Lung Cancer Market Size 2024-2029 ($ Millions)
    Figure 78. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share Forecast by Type (2024-2029)
    Figure 79. Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share Forecast by Application (2024-2029)

Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

• Primary Source
  Players/Suppliers
  Industry Experts
  Distributors/Traders
  Opinion Leaders
  Front-line Staff
  Marketing Executives

  Secondary Source
  Journals and Periodicals
  Government Bodies
  Annual Reports
  Presentations
  Paid Databases
  LPI Internal Repository

• Data Synthesis
  Information Gathering
  Collation of Data
  Estimation of Key Figures
  Analysis of Derived Insights

  Data Validation
  Triangulation with Data Models
  Reference Against Proprietary
  Databases
  Corroboration with Industry Experts

• Qualitative Analysis
  Market drivers
  Market challenges
  Market trends
  Five forces analysis

  Qualitative Analysis
  Market size and forecast
  Market segmentation
  Geographical insights
  Competitive landscape